Report cover image

Active Pharmaceutical Ingredient CDMO Market Size, Share, Trends, & Industry Analysis Report By Product, By Synthesis, By Drugs, By Workflow, By Application, and By Region – Market Forecast, 2025–2034

Publisher Polaris Market Research & Consulting LLP
Published Oct 01, 2025
SKU # PLRS20566098

Description

The active pharmaceutical ingredient CDMO market size is expected to reach USD 225.01 Billion by 2034, according to a new study by Polaris Market Research. The report “Active Pharmaceutical Ingredient CDMO Market Share, Size, Trends, Industry Analysis Report: By Product, By Synthesis, By Drugs, By Workflow, By Application, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Active pharmaceutical ingredient CDMO solutions provide contract development, scale-up, and commercial manufacturing of small-molecule and biologic APIs. These solutions cover traditional APIs, high-potency APIs, and biologics, supporting pharmaceutical companies with efficient, compliant, and scalable production.

Market growth is driven by rising chronic disease prevalence, an aging population, and increasing biologics and specialty drug demand. Moreover, digitalization, AI adoption, and advanced manufacturing technologies are enhancing operational efficiency, regulatory compliance, and global competitiveness.

Active Pharmaceutical Ingredient CDMO Market Report Highlights

Based on product, traditional APIs dominated 2024, driven by widespread generics use.

In terms of synthesis, synthetic APIs led 2024, backed by established chemical manufacturing.

Based on drug type, innovative drugs dominated 2024, supported by novel therapy development.

In terms of workflow, clinical dominated 2024, with increasing early-stage API development.

Based on application, oncology dominated 2024, due to rising cancer therapy demand.

North America dominated 2024, supported by strong pharma infrastructure and outsourcing adoption.

Asia Pacific projected fastest CAGR, fueled by government incentives and expanding CDMO capacity.

Key players in the global market include Lonza Group, Catalent, Samsung Biologics, WuXi AppTec, Piramal Pharma Solutions, Thermo Fisher Scientific Inc., Recipharm, Aurobindo Pharma, Jubilant Pharmova Ltd., Boehringer Ingelheim International GmbH, Curia Global, Inc., and Cambrex.

Polaris Market Research has segmented the market report based on product, synthesis, drug, workflow, application, and region:

By Product Outlook (Revenue, USD Billion, 2020–2034)

Traditional Active Pharmaceutical Ingredient

Highly Potent Active Pharmaceutical Ingredient

Biologics

By Synthesis Outlook (Revenue, USD Billion, 2020–2034)

Synthetic

Biotech

By Drug Outlook (Revenue, USD Billion, 2020–2034)

Innovative

Generics

By Workflow Outlook (Revenue, USD Billion, 2020–2034)

Clinical

Commercial

By Application Outlook (Revenue, USD Billion, 2020–2034)

Oncology

Hormonal

Glaucoma

Cardiovascular disease

Diabetes

Other Application

By Regional Outlook (Revenue, USD Billion, 2020–2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Global Active Pharmaceutical Ingredient CDMO Market Insights
4.1. Active Pharmaceutical Ingredient CDMO Market – Market Snapshot
4.2. Active Pharmaceutical Ingredient CDMO Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Aging population is increasing demand for long-term therapies
4.2.1.2. Rising prevalence of chronic diseases is fueling higher API consumption
4.2.2. Restraints and Challenges
4.2.2.1. Stringent global regulatory requirements increase compliance costs and slow CDMO operations
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. Active Pharmaceutical Ingredient CDMO Market Trends
4.6. Value Chain Analysis
5. Global Active Pharmaceutical Ingredient CDMO Market, by Product
5.1. Key Findings
5.2. Introduction
5.2.1. Global Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
5.3. Traditional Active Pharmaceutical Ingredient
5.3.1. Global Active Pharmaceutical Ingredient CDMO Market, by Traditional Active Pharmaceutical Ingredient, by Region, 2020-2034 (USD Billion)
5.4. Highly Potent Active Pharmaceutical Ingredient
5.4.1.1. Global Active Pharmaceutical Ingredient CDMO Market, by Highly Potent Active Pharmaceutical Ingredient, by Region, 2020-2034 (USD Billion)
5.4.2. Global Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
5.5. Biologics
5.5.1. Global Active Pharmaceutical Ingredient CDMO Market, by Biologics, by Region, 2020-2034 (USD Billion)
6. Global Active Pharmaceutical Ingredient CDMO Market, by Synthesis
6.1. Key Findings
6.2. Introduction
6.2.1. Global Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
6.3. Synthetic
6.3.1. Global Active Pharmaceutical Ingredient CDMO Market, by Synthetic, by Region, 2020-2034 (USD Billion)
6.4. Biotech
6.4.1. Global Active Pharmaceutical Ingredient CDMO Market, by Biotech, by Region, 2020-2034 (USD Billion)
7. Global Active Pharmaceutical Ingredient CDMO Market, by Drug
7.1. Key Findings
7.2. Introduction
7.2.1. Global Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
7.3. Innovative
7.3.1. Global Active Pharmaceutical Ingredient CDMO Market, by Innovative, by Region, 2020-2034 (USD Billion)
7.4. Generics
7.4.1. Global Active Pharmaceutical Ingredient CDMO Market, by Generics, by Region, 2020-2034 (USD Billion)
8. Global Active Pharmaceutical Ingredient CDMO Market, by Workflow
8.1. Key Findings
8.2. Introduction
8.2.1. Global Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
8.3. Clinical
8.3.1. Global Active Pharmaceutical Ingredient CDMO Market, by Clinical, by Region, 2020-2034 (USD Billion)
8.4. Commercial
8.4.1. Global Active Pharmaceutical Ingredient CDMO Market, by Commercial, by Region, 2020-2034 (USD Billion)
9. Global Active Pharmaceutical Ingredient CDMO Market, by Application
9.1. Key Findings
9.2. Introduction
9.2.1. Global Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
9.3. Oncology
9.3.1. Global Active Pharmaceutical Ingredient CDMO Market, by Oncology, by Region, 2020-2034 (USD Billion)
9.4. Hormonal
9.4.1. Global Active Pharmaceutical Ingredient CDMO Market, by Hormonal, by Region, 2020-2034 (USD Billion)
9.5. Glaucoma
9.5.1. Global Active Pharmaceutical Ingredient CDMO Market, by Glaucoma, by Region, 2020-2034 (USD Billion)
9.6. Cardiovascular disease
9.6.1. Global Active Pharmaceutical Ingredient CDMO Market, by Cardiovascular disease, by Region, 2020-2034 (USD Billion)
9.7. Diabetes
9.7.1. Global Active Pharmaceutical Ingredient CDMO Market, by Diabetes, by Region, 2020-2034 (USD Billion)
9.8. Other Application
9.8.1. Global Active Pharmaceutical Ingredient CDMO Market, by Other Application, by Region, 2020-2034 (USD Billion)
10. Global Active Pharmaceutical Ingredient CDMO Market, by Geography
10.1. Key Findings
10.2. Introduction
10.2.1. Active Pharmaceutical Ingredient CDMO Market Assessment, By Geography, 2020-2034 (USD Billion)
10.3. Active Pharmaceutical Ingredient CDMO Market – North America
10.3.1. North America: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.3.2. North America: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.3.3. North America: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.3.4. North America: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.3.5. North America: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.3.6. Active Pharmaceutical Ingredient CDMO Market – U.S.
10.3.6.1. U.S.: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.3.6.2. U.S.: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.3.6.3. U.S.: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.3.6.4. U.S.: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.3.6.5. U.S.: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.3.7. Active Pharmaceutical Ingredient CDMO Market – Canada
10.3.7.1. Canada: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.3.7.2. Canada: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.3.7.3. Canada: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.3.7.4. Canada: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.3.7.5. Canada: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.4. Active Pharmaceutical Ingredient CDMO Market – Europe
10.4.1. Europe: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.4.2. Europe: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.4.3. Europe: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.4.4. Europe: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.4.5. Europe: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.4.6. Active Pharmaceutical Ingredient CDMO Market – UK
10.4.6.1. UK: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.4.6.2. UK: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.4.6.3. UK: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.4.6.4. UK: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.4.6.5. UK: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.4.7. Active Pharmaceutical Ingredient CDMO Market – France
10.4.7.1. France: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.4.7.2. France: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.4.7.3. France: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.4.7.4. France: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.4.7.5. France: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.4.8. Active Pharmaceutical Ingredient CDMO Market – Germany
10.4.8.1. Germany: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.4.8.2. Germany: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.4.8.3. Germany: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.4.8.4. Germany: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.4.8.5. Germany: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.4.9. Active Pharmaceutical Ingredient CDMO Market – Italy
10.4.9.1. Italy: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.4.9.2. Italy: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.4.9.3. Italy: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.4.9.4. Italy: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.4.9.5. Italy: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.4.10. Active Pharmaceutical Ingredient CDMO Market – Spain
10.4.10.1. Spain: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.4.10.2. Spain: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.4.10.3. Spain: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.4.10.4. Spain: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.4.10.5. Spain: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.4.11. Active Pharmaceutical Ingredient CDMO Market – Netherlands
10.4.11.1. Netherlands: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.4.11.2. Netherlands: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.4.11.3. Netherlands: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.4.11.4. Netherlands: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.4.11.5. Netherlands: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.4.12. Active Pharmaceutical Ingredient CDMO Market – Russia
10.4.12.1. Russia: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.4.12.2. Russia: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.4.12.3. Russia: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.4.12.4. Russia: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.4.12.5. Russia: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.4.13. Active Pharmaceutical Ingredient CDMO Market – Rest of Europe
10.4.13.1. Rest of Europe: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.4.13.2. Rest of Europe: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.4.13.3. Rest of Europe: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.4.13.4. Rest of Europe: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.4.13.5. Rest of Europe: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.5. Active Pharmaceutical Ingredient CDMO Market – Asia Pacific
10.5.1. Asia Pacific: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.5.2. Asia Pacific: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.5.3. Asia Pacific: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.5.4. Asia Pacific: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.5.5. Asia Pacific: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.5.6. Active Pharmaceutical Ingredient CDMO Market – China
10.5.6.1. China: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.5.6.2. China: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.5.6.3. China: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.5.6.4. China: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.5.6.5. China: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.5.7. Active Pharmaceutical Ingredient CDMO Market – India
10.5.7.1. India: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.5.7.2. India: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.5.7.3. India: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.5.7.4. India: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.5.7.5. India: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.5.8. Active Pharmaceutical Ingredient CDMO Market – Malaysia
10.5.8.1. Malaysia: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.5.8.2. Malaysia: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.5.8.3. Malaysia: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.5.8.4. Malaysia: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.5.8.5. Malaysia: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.5.9. Active Pharmaceutical Ingredient CDMO Market – Japan
10.5.9.1. Japan: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.5.9.2. Japan: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.5.9.3. Japan: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.5.9.4. Japan: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.5.9.5. Japan: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.5.10. Active Pharmaceutical Ingredient CDMO Market – Indonesia
10.5.10.1. Indonesia: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.5.10.2. Indonesia: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.5.10.3. Indonesia: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.5.10.4. Indonesia: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.5.10.5. Indonesia: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.5.11. Active Pharmaceutical Ingredient CDMO Market – South Korea
10.5.11.1. South Korea: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.5.11.2. South Korea: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.5.11.3. South Korea: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.5.11.4. South Korea: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.5.11.5. South Korea: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.5.12. Active Pharmaceutical Ingredient CDMO Market – Australia
10.5.12.1. Australia: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.5.12.2. Australia: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.5.12.3. Australia: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.5.12.4. Australia: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.5.12.5. Australia: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.5.13. Active Pharmaceutical Ingredient CDMO Market – Rest of Asia Pacific
10.5.13.1. Rest of Asia Pacific: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.5.13.2. Rest of Asia Pacific: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.5.13.3. Rest of Asia Pacific: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.5.13.4. Rest of Asia Pacific: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.5.13.5. Rest of Asia Pacific: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.6. Active Pharmaceutical Ingredient CDMO Market – Middle East & Africa
10.6.1. Middle East & Africa: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.6.2. Middle East & Africa: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.6.3. Middle East & Africa: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.6.4. Middle East & Africa: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.6.5. Middle East & Africa: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.6.6. Active Pharmaceutical Ingredient CDMO Market – Saudi Arabia
10.6.6.1. Saudi Arabia: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.6.6.2. Saudi Arabia: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.6.6.3. Saudi Arabia: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.6.6.4. Saudi Arabia: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.6.6.5. Saudi Arabia: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.6.7. Active Pharmaceutical Ingredient CDMO Market – UAE
10.6.7.1. UAE: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.6.7.2. UAE: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.6.7.3. UAE: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.6.7.4. UAE: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.6.7.5. UAE: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.6.8. Active Pharmaceutical Ingredient CDMO Market – Israel
10.6.8.1. Israel: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.6.8.2. Israel: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.6.8.3. Israel: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.6.8.4. Israel: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.6.8.5. Israel: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.6.9. Active Pharmaceutical Ingredient CDMO Market – South Africa
10.6.9.1. South Africa: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.6.9.2. South Africa: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.6.9.3. South Africa: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.6.9.4. South Africa: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.6.9.5. South Africa: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.6.10. Active Pharmaceutical Ingredient CDMO Market – Rest of Middle East & Africa
10.6.10.1. Rest of Middle East & Africa: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.6.10.2. Rest of Middle East & Africa: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.6.10.3. Rest of Middle East & Africa: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.6.10.4. Rest of Middle East & Africa: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.6.10.5. Rest of Middle East & Africa: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.7. Active Pharmaceutical Ingredient CDMO Market – Latin America
10.7.1. Latin America: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.7.2. Latin America: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.7.3. Latin America: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.7.4. Latin America: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.7.5. Latin America: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.7.6. Active Pharmaceutical Ingredient CDMO Market – Mexico
10.7.6.1. Mexico: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.7.6.2. Mexico: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.7.6.3. Mexico: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.7.6.4. Mexico: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.7.6.5. Mexico: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.7.7. Active Pharmaceutical Ingredient CDMO Market – Brazil
10.7.7.1. Brazil: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.7.7.2. Brazil: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.7.7.3. Brazil: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.7.7.4. Brazil: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.7.7.5. Brazil: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.7.8. Active Pharmaceutical Ingredient CDMO Market – Argentina
10.7.8.1. Argentina: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.7.8.2. Argentina: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.7.8.3. Argentina: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.7.8.4. Argentina: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.7.8.5. Argentina: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
10.7.9. Active Pharmaceutical Ingredient CDMO Market – Rest of Latin America
10.7.9.1. Rest of Latin America: Active Pharmaceutical Ingredient CDMO Market, by Product, 2020-2034 (USD Billion)
10.7.9.2. Rest of Latin America: Active Pharmaceutical Ingredient CDMO Market, by Synthesis, 2020-2034 (USD Billion)
10.7.9.3. Rest of Latin America: Active Pharmaceutical Ingredient CDMO Market, by Drug, 2020-2034 (USD Billion)
10.7.9.4. Rest of Latin America: Active Pharmaceutical Ingredient CDMO Market, by Workflow, 2020-2034 (USD Billion)
10.7.9.5. Rest of Latin America: Active Pharmaceutical Ingredient CDMO Market, by Application, 2020-2034 (USD Billion)
11. Competitive Landscape
11.1. Expansion and Acquisition Analysis
11.1.1. Expansion
11.1.2. Acquisitions
11.2. Partnerships/Collaborations/Agreements/Exhibitions
12. Company Profiles
12.1. Aurobindo Pharma
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Benchmarking
12.1.4. Recent Development
12.2. Boehringer Ingelheim International GmbH
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Benchmarking
12.2.4. Recent Development
12.3. Cambrex
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Benchmarking
12.3.4. Recent Development
12.4. Catalent
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Benchmarking
12.4.4. Recent Development
12.5. Curia Global, Inc.
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Benchmarking
12.5.4. Recent Development
12.6. Jubilant Pharmova Ltd.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Benchmarking
12.6.4. Recent Development
12.7. Lonza Group
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Benchmarking
12.7.4. Recent Development
12.8. Piramal Pharma Solutions
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Benchmarking
12.8.4. Recent Development
12.9. Recipharm
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Product Benchmarking
12.9.4. Recent Development
12.10. Samsung Biologics
12.10.1. Company Overview
12.10.2. Financial Performance
12.10.3. Product Benchmarking
12.10.4. Recent Development
12.11. Thermo Fisher Scientific Inc.
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Product Benchmarking
12.11.4. Recent Development
12.12. WuXi AppTec
12.12.1. Company Overview
12.12.2. Financial Performance
12.12.3. Product Benchmarking
12.12.4. Recent Development

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us